Localization of distinct F-isoprostanes in human atherosclerotic lesions
Journal of Clinical Investigation, ISSN: 0021-9738, Vol: 100, Issue: 8, Page: 2028-2034
1997
- 332Citations
- 58Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations332
- Citation Indexes332
- 332
- CrossRef265
- Captures58
- Readers58
- 58
Article Description
F-Isoprostanes are prostaglandin (PG) isomers formed in situ in cell membranes by peroxidation of arachidonic acid. 8-epi PGF(2α) and IPF(2α)-I are F-isoprostanes produced in humans which circulate in plasma and are excreted in urine. Measurement of F-isoprostanes may offer a sensitive, specific, and noninvasive method for measuring oxidant stress in clinical settings where reactive oxygen species are putatively involved. We determined whether isoprostanes were present in human atherosclerotic lesions, where lipid peroxidation is thought to occur in vivo. 8-epi PGF(2α) ranged from 1.310-3.450 pmol/μmol phospholipid in atherectomy specimens compared with 0.045-0.115 pmol/μmol phospholipid (P < 0.001) in vascular tissue devoid of atherosclerosis. Corresponding values of IPF(2α)-I were 5.6-13.8 vs. 0.16- 0.44 pmol/μmol phospholipid (P < 0.001). Levels of the two isoprostanes in vascular tissue were highly correlated (r = 0.80, P < 0.0001). Immunohistochemical studies confirmed that foam cells adjacent to the lipid necrotic core of the plaque were markedly positive for 8-epi PGF(2α). These cells were also reactive with anti-CD68, an epitope specific for human monocyte/macrophages. 8-epi PGF(2α) immunoreactivity was also detected in cells positive for anti-α-smooth muscle actin antibody, which specifically recognizes vascular smooth muscle cells. Our results indicate that 8-epi PGF(2α) and IPF(2α)-I, two distinct F-isoprostanes and markers of oxidative stress in vivo, are present in human atherosclerotic plaque. Quantitation of these chemically stable products of lipid peroxidation in target tissues, as well as in biological fluids, may aid in the rational development of antioxidant drugs in humans.
Bibliographic Details
American Society for Clinical Investigation
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know